Verona Pharma Plc ADR’s filing revealed that its Chief Medical Officer Rickard Kathleen A. unloaded Company’s shares for reported $0.66 million on Mar 12 ’25. In the deal valued at $8.35 per share,79,264 shares were sold. As a result of this transaction, Rickard Kathleen A. now holds 2,608,976 shares worth roughly $174.31 million.
Then, KATHLEEN RICKARD bought 9,908 shares, generating $621,232 in total proceeds.
Before that, ZACCARDELLI DAVID sold 640,264 shares. Verona Pharma Plc ADR shares valued at $3,205,226 were divested by the President and CEO at a price of $5.01 per share. As a result of the transaction, ZACCARDELLI DAVID now holds 14,367,552 shares, worth roughly $959.9 million.
ROTH MKM initiated its Verona Pharma Plc ADR [VRNA] rating to a Buy in a research note published on January 10, 2025; the price target was $68. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating.
Price Performance Review of VRNA
On Friday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock jump 0.81% to $66.81. Over the last five days, the stock has gained 8.83%. Verona Pharma Plc ADR shares have risen nearly 43.86% since the year began. Nevertheless, the stocks have risen 336.67% over the past one year. While a 52-week high of $70.40 was reached on 03/03/25, a 52-week low of $11.39 was recorded on 01/10/25. SMA at 50 days reached $60.24, while 200 days put it at $37.18.
Levels Of Support And Resistance For VRNA Stock
The 24-hour chart illustrates a support level at 65.89, which if violated will result in even more drops to 64.96. On the upside, there is a resistance level at 67.32. A further resistance level may holdings at 67.83. The Relative Strength Index (RSI) on the 14-day chart is 55.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.18, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 29.71%. Stochastics %K at 64.29% indicates the stock is a holding.
How much short interest is there in Verona Pharma Plc ADR?
A steep rise in short interest was recorded in Verona Pharma Plc ADR stocks on 2025-02-28, growing by 0.72 million shares to a total of 9.0 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 8.29 million shares. There was a rise of 7.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 26, 2022 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $31 price target.
